Navigation Links
Longer life expectancy, aging population necessitate new strategies for prostate cancer care
Date:12/4/2012

The population of the United States is getting older, due not only to aging boomers but also to a four-year increase in life expectancy from 1990 to 2010. An aging population means increased diagnosis of prostate cancer. Statistically, the older the patient at time of diagnosis, the more aggressive the disease and also the less well the patient is likely to tolerate traditional chemotherapies. In sum, we have more, aggressive prostate cancer that can't be targeted by traditional treatments.

Members of the University of Colorado Cancer Center recently published a review in the journal Drugs and Aging describing the modern state of prostate cancer care examining not only new drugs but entirely new classes of drugs that may be effective and well-tolerated in these aging patients.

"For patients with advanced prostate cancer, there are more options than ever before. But with more options comes a more complex decision tree in choosing appropriate therapies," says Elizabeth Kessler, MD, oncology fellow at the University of Colorado Cancer Center and the review's lead author.

First among these options are targeted therapies. Modern targeted therapies are able to selectively kill cancer cells as opposed to accepting high collateral damage in healthy tissue and so frequently have fewer side effects than traditional chemotherapies. (And are thus better tolerated by elderly patients.)

"These are drugs like abiraterone and enzalutamide that have been approved for use in late stage prostate cancer and are now being evaluated for earlier use," Kessler says. Prostate cancer generally depends on androgen hormones like testosterone to survive and grow even after traditional hormone blockade, the body continues to produce minute amounts of testosterone and even this little bit is enough to drive prostate cancer. By completely removing the body's ability to produce testosterone or the cancer's ability to use it, these drugs break the messaging chain that tells prostate cancer to grow. CU Cancer Center researchers have played an important role in the clinical development of both of these drugs.

Researchers are also looking for additional, molecular drivers of prostate cancer, perhaps for example insulin growth factor.

"We're also exploring the use of targeted kinase inhibitors," Kessler says. For example, the drug known as XL184 by Exelixis is currently in clinical trials to target MET and VEGF, "and appears to show effect against bone lesions, the most common location of prostate cancer metastasis," Kessler says.

"Another promising strategy to treat metastatic prostate cancer is immunotherapy," Kessler says. In immunotherapy, drugs, devices or treatments are used to sensitize the body's immune system to attack cancer cells boosting the body's ability to clear itself of cancer. For example, the drug Sipuleucel-T was approved by the FDA in 2010 for treatment of metastatic prostate cancer "but it requires blood to be removed, treated, and reinfused," Kessler says a procedure that can only be accomplished by shipping the patient's blood to facilities in other cities before reinfusing it here. Second generation prostate cancer immunotherapies including Prostvac are in development or clinical trials, including an open trial at the CU Cancer Center.

Finally, researchers are exploring ultra-precise targeting of radiation that rides along with drugs that attach to bone metastases and affects only the tumor cells in the immediate areas of attachment. "One of these drugs is Alpharadin," Kessler says, "which goes only shallowly into bone and so targets lesions without stopping the production of bone marrow."

"There has been a major shift in the acceptance of these drugs," Kessler says. "We're learning to reach for them sooner and more frequently in place of traditional chemotherapies."

This shift means that just as boomers pass age 65 the most common time of prostate cancer diagnosis researchers have a handful of new barriers to put in the path of the disease.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Cancer Care Costs Higher in U.S. Than Europe, But Survival Longer
2. Exercise May Help Patients With High Blood Pressure Live Longer
3. Hispanic lung cancer patients tend to live longer than blacks and whites
4. How That Glass of Red Wine Might Help You Live Longer
5. Joggers Live Longer, Study Says
6. Female and younger athletes take longer to overcome concussions
7. Living longer - variability in infection-fighting genes can be a boon for male survival
8. A Little More Education, a Little Longer Life?
9. Females, Young Athletes Take Longer to Get Over Concussions
10. Deep Brain Stimulation May Offer Longer-Term Relief for Parkinsons
11. Fear of Childbirth Linked to Longer Labor, Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's Hospital ... A topping out ceremony on Friday marked the halfway point of construction and lifting ... in Fall 2018, will serve as a center for innovation aimed at finding new ...
(Date:2/19/2017)... OH (PRWEB) , ... February 19, 2017 , ... Braun ... The JEMS Conference & Exposition, the event will take place February 23-25, 2017 at ... Industries will be in Booth #909 with three new ambulances on display. ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... disruptive innovation in the industry, according to the recent NEJM Catalyst Insights Report ... surveys of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, ...
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... today provides the latest information and contact points to easily connect elderly veterans ... care, assisted living, and elder-care funding. It also conveys material on this year's ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, International ... the exhibit floor for the 2017 HIMSS Conference & Exhibition at ... 2017, more than 40,000 healthcare industry professionals are expected at the conference, where ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... February 18, 2017 Marapharm (OTCQB: ... purchase a Medical Delivery Service with the specific and ... between qualified patients and caregivers. The delivery service is ... in the Coachella Valley, California . ... Angeles area to the West, population 19,000,000. ...
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, Musculoskeletal, ... to grow at a CAGR of 9.4% from 2017-2022 and CAGR ... a CAGR of 9.5% from 2017 to 2027. The market is ... ... you Read on to discover how you can exploit the ...
(Date:2/17/2017)... plc (NYSE, TASE: PRGO) today announced it has received final ... bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg ... methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL ... and children 6 years of age and older. Annual sales ... million.   ...
Breaking Medicine Technology: